CRANBURY, NJ (PRWEB) MARCH 16, 2017
Physicians’ Education Resource® (PER®) will host the 10th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies on March 18, at Crowne Plaza Time Square Manhattan. The program will be led by co-chairs Dr. Daniel P. Petylak, director of Prostate and GU Medical Oncology and director of Prostate Cancer Translational Research Program Yale Cancer Center in New Haven, Connecticut, and Dr. Leonard G. Gomella, chairman of Department of Urology and clinical director of Jefferson Kimmel Cancer Center Network at Thomas Jefferson University in Philadelphia.
Phil Talamo, President of PER® said, “we’re looking forward to this year’s Interdisciplinary Prostate Cancer Congress®, where this multi-disciplinary conference will discuss the latest data in Genitourinary Malignancies.”
The one-day educational meeting’s focal point will be on key clinical topics in the management of genitourinary malignancies, including prognostic/ predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals and immunotherapies, as well as exploring emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. Additionally, this conference will discuss the latest data in GU malignancies, including prostate cancer, renal cell carcinoma and bladder cancers.
For more information and to register please visit: http://www.gotoper.com/go/PRNYGU
About PER®:
Since 1995, PER® has been the educational resource of choice for live and online activities focusing on oncology and hematology. PER® provides high-quality, evidence-based activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. Activities also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management. With the rapid advances occurring in the field of oncology, understanding how to use molecular data to diagnose and stage patients, selecting the most appropriate candidates for novel therapeutic agents, individualizing treatment based on tumor type, and referring patients to clinical trials will continue to ensure the highest level of patient care is provided. PER® serves the oncology healthcare community, including physicians, fellows, advanced practice nurses, nurses, physician assistants, pharmacists, and researchers. PER is part of the Cranbury, N.J.-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com
PER® Media Contacts:
Theresa Burek/609-649-0806
[email protected]
